Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD

We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881).

‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease Treated With Metformin and Sulfonylurea.’ (POSTER NUMBER: P16-5) was presented at the ENDO 2021 Virtual Annual Meeting, March 20 – 23, 2021.

Questions

1. What has the Phase 3 VERTIS CV trial taught us about the cardiovascular safety of ertugliflozin compared with other sodium-glucose cotransporter 2 (SGLT2) inhibitors? (0:17)
2. What was the rationale for the substudy in patients with T2DM and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea? (1:00)
3. What were the findings of the substudy? (1:29)
4. What role is combined therapy with SGLT2 inhibitors likely to play in the future and what questions remain unanswered? (2:24)

Disclosures: Matthew Budoff discloses receiving grant support from Pfizer.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of ENDO 2021 (Virtual).